March 16, 2020 — The Annual Report to the Nation on the Status of Cancer finds that cancer death rates continued to decline from 2001 to 2017 in the United States for all cancer sites combined.
Prostate Cancer
News and new technology innovations concerning how imaging technology can help diagnose and treat prostate cancer can be found on this channel.
-
-
Bill Hartsell, M.D., medical director of the Northwestern Medicine Proton Center in Warrenville, Ill., discusses the outcomes of a trial investigating the use of a hydrogel spacer to hold the rectum away from the prostate during radiation therapy treatments.
-
This is an example of the Mirada DLCExpert deep learning software that automatically identifies organs, segments and auto-contours them as the first step in creating radiation oncology treatment plans. This...
-
Leigh Conroy, Ph.D., physics resident, University Health Network, Princess Margaret Cancer Center, Toronto, Canada, explains how her center is using machine...
-
Bracco Imaging S.p.A. has signed a definitive agreement to acquire Blue Earth Diagnostics, a molecular imaging company based in Oxford, U.K. Subject to customary closing conditions, completion of the transaction is expected in the third quarter of this calendar year.
Age‐standardized, delay‐adjusted overall cancer incidence rates for 2012 through 2016 are illustrated among males and females by racial/ethnic group. Racial/ethnic groups are mutually exclusive. Data for the non‐Hispanic American Indian/Alaska Native (AI/AN) population are restricted to Indian Health Service Purchased/Referred Care Delivery Area (PRCDA) counties. API indicates Asian/Pacific Islander. Chart courtesy of ACS Journals
News | Radiation Oncology | March 16, 2020
March 16, 2020 — The ...
M. Minhaj Siddiqui, M.D., associate professor of surgery at the University of Maryland School of Medicine, discusses benefits of MRI-targeted biopsy to more precisely diagnose aggressive prostate cancers. (c) University of Maryland Greenebaum Comprehensive Cancer Center
News | Prostate Cancer | March 05, 2020
March 5, 2020 — Using a combination of...
From left: Peter Ström, Martin Eklund, Kimmo Kartasalo, Henrik Olsson och Lars Egevad, researchers at Karolinska Institutet in Sweden. Photo courtesy of Stefan Zimmerman
News | Prostate Cancer | January 20, 2020
January 20, 2020 — Researchers at Karolinska Institutet in Sweden and...
Trends in Overall Cancer Mortality Rates by Sex, United States, 1930 to 2017. Rates are age adjusted to the 2000 US standard population. Chart courtesy of the American Cancer Society
News | Radiation Oncology | January 13, 2020
January 13, 2020 — The cancer death rate declined by...
Professor Samer Ezziddin, M.D., from Saarland University/Saarland University Hospital. Image courtesy of Saarland University/Thorsten Mohr
News | Prostate Cancer | January 13, 2020
January 13, 2020 — When a non-scientist tries to imagine a scientist, the image that often arises is one of a somewhat...
Ferrotran (formerly Combidex), based on Ferumoxtran-10, is the only contrast agent which can detect lymph node metastases as small as 2 mm diameter. Standard MRI or CT are not able to detect lymph node metastases smaller than 7 – 8 mm. Since most of the oncologic patients are dying due to metastases, a precise diagnostic is of utmost importance. The detection of small metastases, combined with the very clear and contrast rich MRI image of Ferrotran, enables an earlier and more precise treatment. Therefore, Ferrotran gives the patient a much higher chance of recovery.
News | Prostate Cancer | December 24, 2019
December 24, 2019 — SPL Medical announced today that the first patient has been successfully diagnosed with suspected...
Prof. Dr. Samer Ezziddin from Saarland University/Saarland University Hospital. Photo courtesy of Thorsten Mohr/Saarland University
News | Prostate Cancer | November 28, 2019
November 28, 2019 — Reports of new cancer treatments...
News | Clinical Trials | November 15, 2019
November 15, 2019 — Theragnostics, which is developing innovative...
News | Prostate Cancer | October 16, 2019
October 16, 2019 — GE Healthcare and Theragnostics have entered into a global commercial partnership for a new prostate...
Low four-year rates of gastrointestinal (13.6 percent) and urologic issues (7.6 percent) suggest hypofractionated proton therapy as an alternative to traditional radiotherapy to reduce toxicity.
Feature | Prostate Cancer | October 16, 2019 | By Jeff Zagoudis
Radiation therapy is an important tool in the clinician’s armamentarium for treatment of localized, early-stage...
Videos | Prostate Cancer | September 30, 2019
Bill Hartsell, M.D., medical director of the Northwestern Medicine Proton Center in Warrenville, Ill., discusses the...
News | Brachytherapy Systems | September 13, 2019
September 13, 2019 — Isoray Inc. announced it will spotlight the growing cancer treatment applications of Cesium-131...
Figure 1. 2-D (top) vs 3-D (bottom). The irregularly marginated left tumor mass that bulges the lateral capsule appears three times the volume on the multiplanar 3-D/4-D image reconstruction and shows complete extraprostatic extension. Note: This anterolateral lesion is not clinically palpable.
Feature | Prostate Cancer | September 05, 2019 | By Robert Bard, M.D., DABR, FASLM
Extracapsular extension (ECE) is a major clinical indicator for brachytherapy or external beam treatment of prostate...
News | Radiation Therapy | August 22, 2019
August 22, 2019 — As fiducial markers gain traction in parallel to rising incidences of various cancer affecting lung,...
